Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Yoshiaki, Mihara"'
Autor:
Yoshiaki Mihara, Masataka Hirasaki, Yosuke Horita, Takashi Fujino, Hisayo Fukushima, Yasuo Kamakura, Kousuke Uranishi, Yasumitsu Hirano, Shomei Ryozawa, Masanori Yasuda, Yoshinori Makino, Satomi Shibazaki, Tetsuya Hamaguchi
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Fluoropyrimidine-based postoperative adjuvant chemotherapy is globally recommended for high-risk stage II and stage III colon cancer. However, adjuvant chemotherapy is often associated with severe adverse events and is not highly
Externí odkaz:
https://doaj.org/article/6a5f9b923b2c40fbac8ce5d6d02ba644
Autor:
Yoshiaki Mihara, Masataka Hirasaki, Yosuke Horita, Takashi Fujino, Hisayo Fukushima, Yasuo Kamakura, Kousuke Uranishi, Yasumitsu Hirano, Shomei Ryozawa, Masanori Yasuda, Yoshinori Makino, Satomi Shibazaki, Tetsuya Hamaguchi
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/5f4b12c472a74a5ab15d22b04f49fe02
Autor:
Michio Nakamura, Taro Funakoshi, Shigeki Kataoka, Takahiro Horimatsu, Yoshitaka Nishikawa, Takeshi Matsubara, Takuro Mizukami, Tomoyuki Goto, Kenji Tsuchihashi, Eishi Baba, Takehiko Tsumura, Yoshiaki Mihara, Tetsuya Hamaguchi, Motoko Yanagita, Manabu Muto
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Monitoring proteinuria is important for the management of patients with cancer treated with anti-vascular endothelial growth factor (VEGF) or anti-VEGF receptor (VEGFR) inhibitors (VEGF/Ri). Here we investigated the difference bet
Externí odkaz:
https://doaj.org/article/c037f1bcec82452fbc6674c8c1730fe3
Autor:
Yoshiaki Mihara, Masataka Hirasaki, Yosuke Horita, Takashi Fujino, Hisayo Fukushima, Yasuo Kamakura, Kousuke Uranishi, Yasumitsu Hirano, Shomei Ryozawa, Masanori Yasuda, Yoshinori Makino, Satomi Shibazaki, Tetsuya Hamaguchi
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/1c492865c13d417782ca651080e73c28
Autor:
Yosuke Horita, Yoshiaki Mihara, Masafumi Mizuide, Shin-ei Noda, Tomonori Kawasaki, Masanori Yasuda, Shingo Kato, Shomei Ryozawa, Tetsuya Hamaguchi
Publikováno v:
Internal Medicine; 2024, Vol. 63 Issue 9, p1243-1246, 4p
Autor:
Yoshiaki Mihara, Masataka Hirasaki, Yosuke Horita, Takashi Fujino, Hisayo Fukushima, Yasuo Kamakura, Kousuke Uranishi, Yasumitsu Hirano, Shomei Ryozawa, Masanori Yasuda, Yoshinori Makino, Satomi Shibasaki, Tetsuya Hamaguchi
BackgroundFluoropyrimidine-based adjuvant chemotherapy is globally recommended for postoperative stage III colon cancer and high-risk stage II patients. However, adjuvant chemotherapy is often associated with severe adverse events and is not highly e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0dac3e57d9d43c78be0f4282b8620e9
https://doi.org/10.1101/2022.11.28.518259
https://doi.org/10.1101/2022.11.28.518259
Autor:
Tetsuya Hamaguchi, Shingo Kato, Keiji Nishibeppu, Hiroshi Sato, Isamu Koyama, Yoshiaki Mihara, Yasumitsu Hirano, Shiro Fujihata, Shuichiro Oya, Shinichi Sakuramoto, Gen Ebara, Shohei Fuijta, Kazuaki Matsui, Yosuke Horita, Yutaka Miyawaki, Shin-ei Noda, Hirofumi Sugita, Kojun Okamoto
Publikováno v:
Journal of Gastrointestinal Cancer. 53:420-426
Bleeding from unresectable gastric cancer is a localized condition that adversely affects quality of life. Radiotherapy can be used to treat gastric cancer bleeding when surgery, endoscopic treatment, and intravascular embolization are ineffective. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d09f0d67f3ebaf09587348ed601c77ef
https://doi.org/10.1007/s12029-021-00632-y
https://doi.org/10.1007/s12029-021-00632-y
Autor:
Yoshiaki Mihara, Akihiro Hoshino, Kunitomo Kashiwagi, Koji Matsushita, Naoki Ohashi, Nobumi Tagaya
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 81:1703-1709
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b6c43939a5453e3f32f8ef13e0de260
https://doi.org/10.3919/jjsa.81.1703
https://doi.org/10.3919/jjsa.81.1703
Autor:
Yoshiaki Mihara, Manato Negishi, Akihiro Hoshino, Koji Matsushita, Naoki Ohashi, Masaru Matsumura, Nobumi Tagaya
Publikováno v:
Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons). 45:203-208
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c017d665721935e8082a57b6271b470
https://doi.org/10.4030/jjcs.45.203
https://doi.org/10.4030/jjcs.45.203
Autor:
Ken Naganuma, Yosuke Horita, Keisuke Matsuo, Yu Miyama, Yoshiaki Mihara, Masanori Yasuda, Shintaro Nakano, Tetsuya Hamaguchi
Publikováno v:
Internal medicine (Tokyo, Japan). 61(19)
Nivolumab is an immune-checkpoint inhibitor (ICI) that can induce unique treatment-related toxicities, such as immune-related adverse events (irAEs). Myocarditis is a serious irAE with an incidence between 0.06% and 1.14%. Although the peak onset of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7823a4c99420e40cb03521f3a7d162f
https://pubmed.ncbi.nlm.nih.gov/35249925
https://pubmed.ncbi.nlm.nih.gov/35249925